Skip to main content

Revolution Medicines, Inc.

RVMDW
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001628171

In the last 90 days, Revolution Medicines, Inc. insiders filed 0 open-market purchases and 17 sales; 22 institutions reported holding it in 13F filings for Q2 2026, worth $93.0M in total; no superinvestor holds it.

Other share classesRVMD

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Revolution Medicines, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
17 filings
9 insiders, $76.7M in total
Insiders trading
9
Net value
−$76.7M
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Revolution Medicines, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Revolution Medicines, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Cislini JeffSVP & General Counsel51,776Sep 29, 202610
Mancini AnthonySee Remarks39,765Sep 28, 20268
Anderson Elizabeth MDirector4,333Sep 24, 20263
Sandler Alan B.Chief Development Officer52,868Sep 18, 20261
Kelsey Stephen MichaelSee Remarks286,307Sep 18, 20267
Horn Margaret AChief Operating Officer149,680Sep 18, 20267
Goldsmith Mark ASee Remarks253,342Sep 18, 202613
Anders JackChief Financial Officer119,216Sep 18, 20269
Kim Lorence H.Director0IndirectSep 10, 20263
Patel SushilDirector21,656Jul 1, 20262
Borisy AlexisDirector2,340,075Jun 23, 20261
Horning SandraDirector97,765Jun 23, 20261
Clyburn FrankDirector10,929Jun 23, 20261
Borellini FlaviaDirector26,215Jun 23, 20261
Wang XiaolinSee Remarks116,063Mar 19, 20262
Wei LinChief Medical Officer101,366Mar 19, 20262
Schroeder ThiloDirector760,869IndirectDec 9, 20240
Weber BarbaraDirector13,065Oct 10, 20240
Schmidt Eric ThomasDirector21,251Jun 12, 20230
Exter NeilDirector28,815Jun 17, 20220
Tepper Robert I10% Owner5,104,130Jun 10, 20220
Third Rock Ventures III, L.P.10% Owner5,104,130Jun 10, 20220
TRV GP III, LLC10% Owner5,104,130Jun 10, 20220
Third Rock Ventures GP III, L.P.10% Owner5,104,130Jun 10, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Mar 4, 2022 (view filing)Feb 18, 2020-Mar 4, 2022745 daysLateSchroeder ThiloDirectorPPurchase+1.09M$26.30+$28.6MNew position238.2K after7 lots
Dec 21, 2021 (view filing)Dec 174 daysAnders JackSee RemarksSSale−170$24.41−$4.15K−2.0%8.43K after
Dec 21, 2021 (view filing)Dec 174 daysWang XiaolinSee RemarksSSale−257$24.41−$6.27K−2.1%11.9K after
Dec 21, 2021 (view filing)Dec 174 daysKelsey Stephen MichaelSee RemarksSSale−343$24.41−$8.37K−0.1%251.8K after
Dec 21, 2021 (view filing)Dec 174 daysHorn Margaret ASee RemarksSSale−491$24.41−$12.0K−1.9%25.5K after
Dec 21, 2021 (view filing)Dec 174 daysGoldsmith Mark ASee RemarksSSale−1.57K$24.41−$38.3K−1.9%82.6K after
Sep 21, 2021 (view filing)Sep 174 daysAnders JackSee RemarksSSale−166$30.02−$4.98K−2.0%8.19K after
Sep 21, 2021 (view filing)Sep 174 daysKelsey Stephen MichaelSee RemarksSSale−335$30.02−$10.1K−0.1%252.2K after
Sep 21, 2021 (view filing)Sep 174 daysWang XiaolinSee RemarksSSale−250$30.02−$7.50K−2.0%12.2K after
Sep 21, 2021 (view filing)Sep 174 daysGoldsmith Mark ASee RemarksSSale−1.53K$30.02−$46.0K−3.2%46.5K after
Sep 21, 2021 (view filing)Sep 174 daysHorn Margaret ASee RemarksSSale−479$30.02−$14.4K−1.8%26.0K after